#1 Clinical Trials Search in Europe

Pemetrexed Disodium

Pemetrexed Disodium, also known by its brand name Alimta, is a chemotherapy drug being studied in clinical trials for various types of cancer. These trials aim to evaluate its effectiveness, safety, and optimal dosing in different patient populations. The drug works by stopping cancer cells from dividing and growing, potentially offering new treatment options for patients with advanced or recurrent cancers.

Table of Contents

What is Pemetrexed Disodium?

Pemetrexed Disodium is a chemotherapy drug used to treat various types of cancer. It’s also known by its brand names Alimta® and LY231514[1][2]. This medication is part of a class of drugs called antimetabolites, which work by interfering with the growth of cancer cells.

How Does Pemetrexed Disodium Work?

Pemetrexed Disodium works by blocking certain enzymes that cancer cells need to grow and divide. Specifically, it stops the action of enzymes involved in making DNA and other important molecules that cells need to survive and multiply. By doing this, Pemetrexed Disodium can slow down or stop the growth of cancer cells[2].

What Conditions Does Pemetrexed Disodium Treat?

Pemetrexed Disodium is used to treat several types of cancer, including:

  • Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer that affects the cells lining the airways. Pemetrexed is often used in combination with other drugs to treat advanced stages of this disease[3][4].
  • Malignant Pleural Mesothelioma: This is a rare cancer that affects the lining of the lungs and chest wall, often caused by exposure to asbestos.
  • Gastric Cancer: Some studies have explored the use of Pemetrexed in treating advanced or recurrent stomach cancer[1].
  • Chondrosarcoma: This is a type of bone cancer that has been studied for treatment with Pemetrexed[5].
  • Cervical Cancer: Research has been conducted on using Pemetrexed for recurrent cervical cancer[6].
  • Endometrial Cancer: Studies have looked at Pemetrexed’s effectiveness in treating persistent or recurrent endometrial cancer[7].
  • Ovarian and Primary Peritoneal Cancer: Pemetrexed has been studied for use in these types of cancers when they are resistant to platinum-based treatments[8].
  • Gestational Trophoblastic Tumor: This is a rare cancer that can occur during pregnancy, and Pemetrexed has been studied as a treatment option[9].

How is Pemetrexed Disodium Administered?

Pemetrexed Disodium is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The infusion usually takes about 10 minutes and is given once every 21 days. This 21-day period is called a treatment cycle[1][4].

To help reduce side effects, patients are often given additional medications:

  • Folic acid: You’ll typically start taking folic acid supplements by mouth about a week before your first dose of Pemetrexed and continue throughout your treatment.
  • Vitamin B12: You’ll receive vitamin B12 injections, usually starting about a week before treatment and continuing every 9 weeks during treatment.
  • Corticosteroids: You may be given a corticosteroid medication like dexamethasone to help prevent skin reactions.

Potential Side Effects

Like all chemotherapy drugs, Pemetrexed Disodium can cause side effects. Some common side effects may include:

  • Fatigue
  • Nausea and vomiting
  • Loss of appetite
  • Diarrhea or constipation
  • Skin rash
  • Low blood cell counts, which can increase risk of infection or bleeding

Your healthcare team will monitor you closely for these and other potential side effects. It’s important to report any new symptoms or changes in how you feel to your doctor[4].

Ongoing Research and Clinical Trials

Researchers continue to study Pemetrexed Disodium to understand how it can be used most effectively. Some areas of ongoing research include:

  • Combination therapies: Studies are looking at how Pemetrexed works when combined with other cancer treatments, such as immunotherapy drugs like Pembrolizumab[3].
  • Personalized treatment: Researchers are investigating whether certain genetic markers can predict how well a patient will respond to Pemetrexed. For example, some studies are looking at the role of genes like methylthioadenosine phosphorylase (MTAP) in treatment response[5].
  • New cancer types: Clinical trials are exploring the use of Pemetrexed in cancers where it’s not currently a standard treatment, such as certain childhood cancers[2].
  • Quality of life: Studies are assessing how Pemetrexed affects patients’ overall well-being and quality of life during treatment[4].

If you’re interested in participating in a clinical trial involving Pemetrexed Disodium, talk to your oncologist about what options might be available to you.

Aspect Details
Drug Name Pemetrexed Disodium (Brand name: Alimta)
Cancer Types Studied Gastric, Chondrosarcoma, Cervical, Endometrial, Ovarian, Primary Peritoneal, Gestational Trophoblastic Tumor, Non-Small Cell Lung Cancer, Various Solid Tumors
Administration Intravenous, typically 500 mg/m2 every 21 days
Supplementation Oral folic acid daily, vitamin B12 injections
Treatment Duration Until disease progression or unacceptable toxicity
Main Study Objectives Efficacy, safety, optimal dosing, pharmacokinetics
Special Considerations Studies in patients with varying degrees of kidney function

FAQ

  • What types of cancer is Pemetrexed Disodium being studied for? Pemetrexed Disodium is being studied in clinical trials for various types of cancer, including gastric cancer, chondrosarcoma, cervical cancer, endometrial cancer, ovarian cancer, primary peritoneal cancer, gestational trophoblastic tumor, non-small cell lung cancer, and other solid tumors.
  • How is Pemetrexed Disodium administered in these trials? In most trials, Pemetrexed Disodium is administered intravenously (through a vein) over 10 minutes, typically every 21 days. The dosage is often 500 mg/m2, but this may vary depending on the specific trial and patient characteristics.
  • Are there any additional supplements given with Pemetrexed Disodium? Yes, patients in these trials are usually instructed to take oral folic acid daily and receive vitamin B12 injections. These supplements are given to help reduce the side effects of Pemetrexed Disodium.
  • How long do patients receive Pemetrexed Disodium treatment in these trials? Treatment duration varies, but generally, patients continue receiving Pemetrexed Disodium until disease progression or unacceptable toxicity occurs. In some trials, additional cycles are given after achieving a complete response.
  • What are the main goals of these clinical trials? The main goals of these trials include determining the effectiveness of Pemetrexed Disodium in treating various cancers, assessing its safety and side effects, finding the optimal dosage, and studying how it works in patients with different levels of kidney function.

Ongoing Clinical Trials on Pemetrexed Disodium

  • Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Greece Hungary Italy Poland Spain

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

  • Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Finland France Germany Greece +8

  • Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain Sweden

  • Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

    Not yet recruiting

    4 1 1 1
    Investigated drugs:
    Italy

  • Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Spain

  • Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland

Glossary

  • Pemetrexed Disodium: A chemotherapy drug that works by stopping cancer cells from dividing and growing. It's also known by the brand name Alimta.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, such as new ways to prevent, detect, or treat diseases.
  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Recurrent Cancer: Cancer that has come back after a period of time during which it could not be detected.
  • Intravenous (IV): Given through a vein.
  • Toxicity: The extent to which something is poisonous or harmful.
  • Progression-free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Dose-limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or level of that drug.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.

References

  1. https://clinicaltrials.gov/study/NCT01953419
  2. https://clinicaltrials.gov/study/NCT00070473
  3. https://clinicaltrials.gov/study/NCT04166487
  4. https://clinicaltrials.gov/study/NCT01639001
  5. https://clinicaltrials.gov/study/NCT00107419
  6. https://clinicaltrials.gov/study/NCT00087113
  7. https://clinicaltrials.gov/study/NCT00087100
  8. https://clinicaltrials.gov/study/NCT00087087
  9. https://clinicaltrials.gov/study/NCT00096187